Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

46.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
28 Stocks Moving In Monday's Mid-Day Session
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical... 
Via Benzinga
Exposures Product Safety
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. 
Via InvestorPlace
Exposures Product Safety
Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug
Protagonist Therapeutics can now restart dosing patients in its rusfertide studies. 
Via Investor's Business Daily
Exposures Product Safety
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program
The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy
When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. 
Via InvestorPlace
58 Biggest Movers From Yesterday
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... 
Via Benzinga
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 70.1% to $9.68 in pre-market trading following an announcement from management that the company entered into a revenue... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
32 Stocks Moving In Tuesday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
48 Biggest Movers From Yesterday
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
Why Protagonist Therapeutics Stock Plunged Today
The FDA has placed a clinical hold on testing of rusfertide. 
Via The Motley Fool
Exposures Product Safety
Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge
Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also fell, dropping 2.58% to 4,318.67. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. Trading volume for this security as of 12:30 EST is 3.... 
Via Benzinga
What 5 Analyst Ratings Have To Say About Protagonist Therapeutics
Protagonist Therapeutics (NASDAQ:PTGX) has observed the following analyst ... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher
Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, dropping 1.64% to 4,360.41. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Stocks Moving In Monday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B
Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also fell, dropping 1.54% to 4,364.65. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021
Upgrades For Methanex Corp (NASDAQ: 
Via Benzinga
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
PTGX Stock: Why Protagonist Therapeutics Is Plunging 60% Today
Today, investors in Protagonist Therapeutics and PTGX stock have seen an absolutely massive decline due to an FDA hold of its clinical trial. 
Via InvestorPlace
Exposures Product Safety
Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet
Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Protagonist Therapeutics Stock Is Tanking Today
The FDA put a clinical hold on one of the biotech's new drug candidates. 
Via The Motley Fool
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS 
Via Benzinga
Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher
Midway through trading Friday, the Dow traded down 0.51% to 34,572.50 while the NASDAQ fell 0.78% to 15,062.99. The S&P also fell, dropping 0.72% to 4,441.64. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Highly Rated Protagonist Stock Takes A Hit After Study Mice Develop Tumors
Mice in Protagonist's study developed tumors under their skin. 
Via Investor's Business Daily
Exposures Product Safety
Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher
Following the market opening Friday, the Dow traded down 0.37% to 34,622.25 while the NASDAQ fell 0.58% to 15,094.19. The S&P also fell, dropping 0.55% to 4,449.03. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.